Related Research Articles
Acute disseminated encephalomyelitis (ADEM), or acute demyelinating encephalomyelitis, is a rare autoimmune disease marked by a sudden, widespread attack of inflammation in the brain and spinal cord. As well as causing the brain and spinal cord to become inflamed, ADEM also attacks the nerves of the central nervous system and damages their myelin insulation, which, as a result, destroys the white matter. The cause is often a trigger such as from viral infection or vaccinations.
Multiplesclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time. In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances. In the progressive forms of MS, bodily function slowly deteriorates and disability worsens once symptoms manifest and will steadily continue to do so if the disease is left untreated.
Para table tennis is a parasports which follows the rules set by the International Table Tennis Federation (ITTF). The usual table tennis rules are in effect with slight modifications for wheelchair athletes. Athletes from disability groups can take part. Athletes receive classifications between 1-11. Classes 1-5 are for those in wheelchairs and classes 6-10 for those who have disabilities that allow them to play standing. Within those groups, the higher classification means the more function the athlete has. Class 11 is defined for players with an intellectual disability.
Amantadine, sold under the brand name Gocovri among others, is a medication used to treat dyskinesia associated with parkinsonism and influenza caused by type A influenzavirus, though its use for the latter is no longer recommended because of widespread drug resistance. It acts as a nicotinic antagonist, dopamine agonist, and noncompetitive NMDA antagonist. The antiviral mechanism of action is antagonism of the influenzavirus A M2 proton channel, which prevents endosomal escape.
Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.
HIV-associated neurocognitive disorders (HAND) are neurological disorders associated with HIV infection and AIDS. It is a syndrome of progressive deterioration of memory, cognition, behavior, and motor function in HIV-infected individuals during the late stages of the disease, when immunodeficiency is severe. HAND may include neurological disorders of various severity. HIV-associated neurocognitive disorders are associated with a metabolic encephalopathy induced by HIV infection and fueled by immune activation of macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. The essential features of HIV-associated dementia (HAD) are disabling cognitive impairment accompanied by motor dysfunction, speech problems and behavioral change. Cognitive impairment is characterised by mental slowness, trouble with memory and poor concentration. Motor symptoms include a loss of fine motor control leading to clumsiness, poor balance and tremors. Behavioral changes may include apathy, lethargy and diminished emotional responses and spontaneity. Histopathologically, it is identified by the infiltration of monocytes and macrophages into the central nervous system (CNS), gliosis, pallor of myelin sheaths, abnormalities of dendritic processes and neuronal loss.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process. IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis, but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.
Multiple sclerosis can cause a variety of symptoms: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech (dysarthria) or swallowing (dysphagia), visual problems, fatigue and acute or chronic pain syndromes, bladder and bowel difficulties, cognitive impairment, or emotional symptomatology. The main clinical measure in progression of the disability and severity of the symptoms is the Expanded Disability Status Scale or EDSS.
Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.
Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS). Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of these 17 amino acids is
The Gross Motor Function Classification System or GMFCS is a 5 level clinical classification system that describes the gross motor function of people with cerebral palsy on the basis of self-initiated movement abilities. Particular emphasis in creating and maintaining the GMFCS scale rests on evaluating sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities; the need for walkers, crutches, wheelchairs, or canes / walking sticks; and to a much lesser extent, the actual quality of movement.
Malignant multiple sclerosis is used to describe MS patients who reach significant level of disability in a short period of time. Malignant MS cases are not common, less than 5% of patients with MS experience this type of progression.
Disability sports classification is a system that allows for fair competition between people with different types of disabilities.
Para-equestrian classification is a system for para-equestrian sport is a graded system based on the degree of physical or visual disability and handled at the international level by the FEI. The sport has eligible classifications for people with physical and vision disabilities. Groups of eligible riders include The sport is open to competitors with impaired muscle power, athetosis, impaired passive range of movement, hypertonia, limb deficiency, ataxia, leg length difference, short stature, and vision impairment. They are grouped into five different classes to allow fair competition. These classes are Grade I, Grade II, Grade III, Grade IV, and Grade V(Grade Names Changed as of Jan 2017). The para-equestrian classification does not consider the gender of the rider, as equestrines compete in mixed gender competitions.
John Francis Kurtzke was a neuroepidemiologist and Professor of Neurology at Georgetown University who is best known for his creation of the Expanded Disability Status Scale and for his research on multiple sclerosis (MS). After graduating from Cornell University Medical College in 1952, Dr. Kurtzke started his career in the field of Neurology as Chief of the Neurology Service at the Veteran's Affairs (VA) Medical Centers in Coatesville, Pennsylvania, from 1956 to 1963, and then in Washington, DC, from 1963 to 1995, where he became Professor of Neurology at Georgetown University. At the time of his death, he held the title of Professor Emeritus at Georgetown University.
The Multiple Sclerosis Functional Composite (MSFC) is a clinical trial outcome measure of assessing the severity of multiple sclerosis primarily used in research. The score is based on a combination of timed tests of walking, arm function, and cognitive ability. It was developed over two years from 1994 to 1996 by the National Multiple Sclerosis Society.
Les Autres sport classification is system used in disability sport for people with locomotor disabilities not included in other classification systems for people with physical disabilities. The purpose of this system is to facilitate fair competition between people with different types of disabilities, and to give credibility to disability sports. It was designed and managed by International Sports Organization for the Disabled (ISOD) until the 2005 merger with IWAS, when management switched to that organization. Classification is handled on the national level by relevant sport organizations.
LA6 is a Les Autres sport classification is an ambulatory sport classification for a sportsperson with a disability that impacts their locomotor function. People in this class have a minimal locomotor disability that tends to impact one of their upper limbs or knees. The class includes people with arthritis and osteoporosis, or ankylosis of the knee.
Age-related mobility disability is a self-reported inability to walk due to impairments, limited mobility, dexterity or stamina. It has been found mostly in older adults with decreased strength in lower extremities.
References
- 1 2 3 Kurtzke JF (November 1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology. 33 (11): 1444–52. doi: 10.1212/WNL.33.11.1444 . PMID 6685237.
- ↑ Piryonesi, S. Madeh; Rostampour, Sorour; Piryonesi, S. Abdurrahman (2021-04-01). "Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms". Multiple Sclerosis and Related Disorders. 49: 102740. doi:10.1016/j.msard.2021.102740. ISSN 2211-0348. PMID 33450500. S2CID 231624230.
- ↑ Collins CD, Ivry B, Bowen JD, Cheng EM, Dobson R, Goodin DS, Lechner-Scott J, Kappos L, Galea I (September 2016). "A comparative analysis of Patient-Reported Expanded Disability Status Scale tools". Multiple Sclerosis. 22 (10): 1349–58. doi:10.1177/1352458515616205. PMC 5015760 . PMID 26564998.
- 1 2 Meyer-Moock, Sandra; Feng, You-Shan; Maeurer, Mathias; Dippel, Franz-Werner; Kohlmann, Thomas (2014-03-25). "Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis". BMC Neurology. 14: 58. doi: 10.1186/1471-2377-14-58 . ISSN 1471-2377. PMC 3986942 . PMID 24666846.
- 1 2 Validity of Outcome Measures. Canadian Agency for Drugs and Technologies in Health. May 2018.